On July 31, 2021, CARsgen Therapeutics Group (CARsgen) and Shanghai Cancer Institute of Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine (Shanghai Cancer Institute) reached a strategic collaboration to enhance the transformation and application of scientific and technological achievements and signed the framework agreement. Professor Liu Yingbin, Director of the Shanghai Cancer Institute, and Dr. Li Zonghai, Chairman and CEO of CARsgen, jointly signed the agreement.

This collaboration is an expansion to the previous collaboration reached between Shanghai Cancer Institute and CARsgen in August 2015. Two parties will strengthen the collaboration to better integrate scientific research and industry to maximize the mutual value. Through this cooperation, CARsgen will continue to innovate and utilize advanced knowledge and cutting-edge technologies to better utilize the research resources and form the Group's competitive advantage in scientific and technological capabilities and product pipeline.

Founded in 1958, Shanghai Cancer Institute is committed to basic science and applied scientific research on tumors, including the epidemiology and etiology of malignant tumors, the exploration of tumor pathogenesis, and the development of genetic diagnosis and gene therapy, cell and immunological diagnosis and treatment, and other basic and applied research for innovative cancer prevention and treatment approaches. Since inception in 2014, CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. We have built an integrated cell therapy platform with in-house capabilities that span from target discovery, lead antibody development, clinical trials to commercial-scale manufacturing. We have internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR-T cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors and reducing treatment costs. We have 11 product candidates fully developed in house with global rights, covering the conventional CAR-T, next-generation CAR-T and allogeneic CAR-T cells. Among our product pipeline, CT041 is a globally potential first-in-class, autologous CAR-T product candidate against CLDN18.2 being developed for the treatment of CLDN18.2 positive solid tumors with a primary focus on gastric/gastroesophageal junction cancer and pancreatic cancer. CT041 is the only CLDN18.2-targeted CAR-T product candidate globally that is being studied in clinical trials with IND approvals from the FDA and the NMPA and has received Orphan Drug designation from the U.S. FDA and the Orphan Medicinal Product designation from the EMA.

HONG KONG, June 19, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (the "Company", stock code: 2171.HK) today announced that the Company's Shares have been traded on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code "2171.HK".

SHANGHAI, March 1, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited, a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan designation for CT041, CARsgen's first-in-class Claudin 18.2 (CLDN18.2) targeted CAR-T product candidate for the treatment of gastric cancer. CT041 consists of the patient's own T cells, genetically modified to express a humanized anti-CLDN18.2 chimeric antigen receptor (CAR) to treat patients with CLDN18.2-positive tumors.

SHANGHAI, Dec. 6, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company, announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed and/or refractory multiple myeloma (RRMM). The data were presented virtually in two oral sessions and one poster session at the 62^nd Annual Meeting of the American Society of Hematology (ASH) held December 5-8, 2020.

SHANGHAI, Nov. 20, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company, today announced that data from its global multiple myeloma program will be presented, including two oral presentations and one poster session, at the 62^nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually December 5-8, 2020.

SHANGHAI, Nov. 2, 2020 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited ("CARsgen"), a leading biotechnology company focused on innovation and development of chimeric antigen receptor (CAR) T-cell therapeutics, today announced the completion of a USD 186 million Series C Equity Financing. The Series C funding was led by a leading private equity firm Loyal Valley Capital and joined by Lilly Asia Ventures, Shiyu Capital, and Summer Capital. Existing investor South China Venture Capital also participated in the round.  

SHANGHAI, Oct. 5, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that the United States (US) Food and Drug Administration (FDA) has granted orphan drug designation to one of CARsgen's first-in-class drug candidates, CT041, for the treatment of gastric and gastroesophageal junction adenocarcinoma. CT041 is a humanized anti-claudin18.2 autologous chimeric antigen receptor (CAR) T-cell product and is targeted to treat patients with claudin18.2-positive tumors.

SHANGHAI, Aug. 20, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for the first-in-class drug candidate CT041, autologous chimeric antigen receptor (CAR) T cells for the treatment of claudin18.2-positive solid tumors.

SHANGHAI, April 27, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on CARsgen's application for orphan designation of its investigational CT053 CAR T-cell therapy, fully human anti-BCMA (B cell maturation antigen) autologous chimeric antigen receptor (CAR) T cells for the treatment of multiple myeloma. CT053 was previously granted orphan drug designation by the US Food and Drug Administration in August 2019.